References
- Camp D, Davis RA, Campitelli M, Ebdon J, Quinn RJ. 2012. Drug-like properties: guiding principles for the design of natural product libraries. J Nat Prod. 75(1):72–81.
- Chan STS, Pearce AN, Page MJ, Kaiser M, Copp BR. 2011. Antimalarial beta-carbolines from the New Zealand ascidian Pseudodistoma opacum. J Nat Prod. 74(9):1972–1979.
- Dashti Y, Grkovic T, Abdelmohsen UR, Hentschel U, Quinn RJ. 2014. Production of induced secondary metabolites by a co-culture of sponge-associated Actinomycetes, Actinokineospora sp. EG49 and Nocardiopsis sp. RV163. Mar Drugs. 12(5):3046–3059.
- Dashti Y, Vial M-L, Wood SA, Mellick GD, Roullier C, Quinn RJ. 2015. Kororamide B, a brominated alkaloid from the bryozoan Amathia tortuosa and its effects on Parkinson's disease cells. Tetrahedron. 71(41):7879–7884.
- Jiang W, Zhou W, Othman R, Uchida H, Watanabe R, Suzuki T, Sakamoto B, Nagai H. 2018. A new malyngamide from the marine cyanobacterium Moorea producens. Nat Prod Res. 32(1):97–104.
- Kondo Y, Takemoto T. 1973. The structure of a new β-carboline alkaloid from Picrasma ailanthoides PLANCHON. Chem Pharm Bull. 21(4):837–839.
- Nagarajan M, Maruthanayagam V, Sundararaman M. 2012. A review of pharmacological and toxicological potentials of marine cyanobacterial metabolites. J Appl Toxicol. 32(3):153–185.
- Tan LT. 2007. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry. 68(7):954–979.